- Age >= 18 years 2. Patients with haematological malignancies receiving neutropenia (<
0.5 x 109/L) inducing chemotherapy (+/- TBI) requiring hospitalisation.
3. Negative pregnancy test if the patient is of childbearing potential 4. Informed consent
- . Previous treatment with growth hormone 2.Unstable psychiatric conditions 3.
Uncontrolled endocrine disorders 4.Chronic severe liver disease: AST or ALT>3x upper
limit of normal range 5. Chronic severe renal disease: creatinine>150 µM or repeated
positive test for haematuria or proteinuria 6. Severe congestive heart failure 7.
Aortic stenosis associated with clinical symptoms eg syncope of angina pectoris 8.
Hypertrophic cardiomyopathy 9. Uncontrolled hypertension (diastolic blood-pressure >
105 mm Hg) 10. Diabetes mellitus that is not well controlled with
insulin/antidiabetic drugs 11. Severe respiratory disease 12. Known or suspected
allergy to growth hormone or any of its constituents 13. History of drug or alcohol
abuse within two years prior to study enrolment 14. Exposure to another
investigational medication or device currently or within three months prior to